Replies to post #112375 on Biotech Values

[DewDiligence]

PFE’s Crizotinib gets FDA priority review for ALK+ NSCLC:

http://finance.yahoo.com/news/Pfizer-Announces-Simultaneous-bw-1580950951.html?x=0&.v=1

The exact PDUFA date is not disclosed; it is presumably in late Sep or early Oct. An NDA has also been submitted in Japan.